Clinical Switching Strategies of Various Antidepressants to Vortioxetine in the PREDDICT Trial | Zendy

Natalie Mills | Zendy; Emma Sampson | Zendy; Célia Fourrier | Zendy; Bernhard T. Baune | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Clinical Switching Strategies of Various Antidepressants to Vortioxetine in the PREDDICT Trial

Author(s) -

Natalie Mills,

Emma Sampson,

Célia Fourrier,

Bernhard T. Baune

Publication year - 2020

Publication title -

the international journal of neuropsychopharmacology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.897

H-Index - 107

eISSN - 1469-5111

pISSN - 1461-1457

DOI - 10.1093/ijnp/pyaa092

Subject(s) - vortioxetine , mirtazapine , antidepressant , agomelatine , major depressive disorder , placebo , psychology , serotonin reuptake inhibitor , medicine , psychiatry , anxiety , mood , alternative medicine , pathology

Partial response to antidepressant medication as well as relapse and treatment resistance are common in major depressive disorder (MDD). Therefore, for most patients with MDD, there will be a need to consider changing antidepressant medication at some stage during the course of the illness. The PREDDICT study investigates the efficacy of augmenting vortioxetine with celecoxib.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research